research Phase I Clinical Testing Antimalarial Drugs.
Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.
Search
for
Sort by
Research
450-480 / 1000+ results
research Prednisolone
A woman's hair grew back after she stopped taking the Parkinson's disease medication pramipexole.
research Bibliometric analysis and visualization of research trends on HIV-1 capsid inhibitors (2000–2022)
Research on HIV-1 capsid inhibitors has progressed significantly, with the U.S. leading in contributions.
research Oral Presentations
The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
research P063 Tracking down autoantibodies
A man developed autoimmune symptoms after the Pfizer COVID-19 vaccine, highlighting the need for thorough vaccine safety checks.
research A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy
Extended-release valproate effectively reduced seizures and improved quality of life in epilepsy patients over 6 months, with some side effects.
research Freeze-Drying of Platelet-Rich Plasma: The Quest for Standardization
The document concludes that freeze-dried platelet-rich plasma shows promise for medical use but requires standardization and further research.
research Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles
Six existing drugs may help block virus entry in COVID-19.
research NIPAL4 mutation c.527C˃A identified in Romanian patients with autosomal recessive congenital ichthyosis
The NIPAL4 mutation c.527C>A is common in Romanian patients with autosomal recessive congenital ichthyosis.
research Design and synthesis of potential nano-carrier for delivery of diphencyprone to hair follicle
research Can Plasma Rich in Growth Factors Be Safe for Parental Use? A Safety Study in the Canine Model
PRP derivatives are likely safe for therapeutic use without harmful effects.
research Valproate-induced thrombocytopenia
Valproic acid can cause low platelet counts, especially at high doses or in elderly patients.
research Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
research Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
Infectious virus was not found after the third remdesivir dose, suggesting early end of isolation is possible.
research Hereditary vitamin D resistant rickets (HVDRR) case series: phenotype, genotype, conventional treatment, and adjunctive cinacalcet therapy
Cinacalcet may help treat hereditary vitamin D resistant rickets safely.
research Nonalimental Scurvy With Relapse Symptoms After Stopping Oral Vitamin C Supplementation
A 3-year-old girl developed scurvy symptoms that improved with vitamin C but relapsed when supplementation stopped.
research DIAGNOSTYKA, ETIOLOGIA, EPIDEMIOLOGIA I LECZENIE GUZÓW REGIONU GŁOWY I SZYI U DZIECI I MŁODZIEŻY
Rhabdomyosarcoma is the most common head and neck cancer in children, requiring complex treatment.
research A reasonable Response to Diphensiprone in Pediatric Alopecia Patient: A Case Report
Topical diphencyprone effectively treated a 9-year-old boy's alopecia areata with fewer side effects.
research Virtual Screening of Potential Inhibitors for SARS-CoV-2 Main Protease
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
research Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
The Pfizer COVID-19 vaccine may rarely trigger nail psoriasis.
research Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model
The hepatitis B vaccine did not cause hair loss in the tested mice.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research Disruption of anthrax toxin receptor 1 in pigs leads to a rare disease phenotype and protection from senecavirus A infection
Removing anthrax toxin receptor 1 in pigs prevents Senecavirus A infection and causes a rare disease similar to GAPO syndrome.
research Why we should treat COVID-19 Long-Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes are likely COVID antigen-specific
Convalescent Plasma Therapy may help treat COVID-19 Long-Hauler symptoms.
research Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
COVID-19 vaccines can trigger autoimmune flares but are still beneficial for patients with autoimmune conditions.
research Protective Role of Cepharanthine Against Equid Herpesvirus Type 8 Through AMPK and Nrf2/HO-1 Pathway Activation
Cepharanthine may help treat Equid herpesvirus type 8 by reducing oxidative stress.
research Neonatal screening in Sweden and disease-causing variants in phenylketonuria, galactosaemia and biotinidase deficiency
The Swedish neonatal screening program effectively detects PKU, galactosaemia, and biotinidase deficiency with low false positives.
research Helicobacter pylori infection and polycystic ovary syndrome in adolescent and young adult patients
The study found no significant link between Helicobacter pylori infection and polycystic ovary syndrome in young females.
research Transient skin stretching stimulates immune surveillance and promotes vaccine delivery via hair follicles
Skin stretching can improve vaccine delivery through hair follicles and boost immune response.
research Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.